Compare Bit Digital Inc (BTBT) vs TG Therapeutics Inc (TGTX) Price & Performance

BTBT trades at $1.46, up 12.31% today, but the technical outlook is bearish with selling pressure outweighing buying signals. Fundamentally, the company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45% in 2026, indicating severe profitability challenges despite a gross margin above 55%. Recent earnings have missed expectations in two of the last three quarters.

The outlook remains challenged by persistent losses and negative cash flow from operations. While analyst coverage is limited and currently shows a 100% buy rating from two firms, significant execution risk and reliance on financing activities to offset operational cash burns present substantial headwinds for shareholder value appreciation in the near term.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.